Skip to main content
SpringerLink
Log in

Comment on: ‘Pirfenidone Tablets in Idiopathic Pulmonary Fibrosis: A Profile of Their Use’

  • Letter to the Editor
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lyseng-Williamson KA. Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. Drugs Ther Perspect. 2018;234(1):8–15.

    Article  Google Scholar 

  2. Esbriet (pirfenidone) tablets and capsules: summary of product characteristics. London: European Medicines Agency; 2017.

  3. Cottin V, Crestani B, Cadranel J, et al. French practical guidelines for the diagnois and management of idiopathic pulmonary fibrosis—2017 update: full-length version. Rev Mal Respir. Epub 2107 Sep 21. https://doi.org/10.1016/j.rmr.2017.07.018.

  4. Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. J Intern Med. 2017;281(2):149–66.

    Article  PubMed  Google Scholar 

  5. Xaubet A, Molina-Molina M, Acosta O, et al. Guidelines for the medical treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol. 2017;53(5):263–9.

    Article  PubMed  Google Scholar 

  6. Ofev (nintedanib): summary of product characteristics. London: European Medicines Agency; 2017.

Download references

Funding

The preparation of this letter was not supported directly by any external funding.

Author information

Authors and Affiliations

  1. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

    Susanne Stowasser & Manuel Quaresma

  2. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

    Markus Rieck

Authors
  1. Susanne Stowasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel Quaresma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus Rieck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Stowasser.

Ethics declarations

Conflict of interest

S. Stowasser and M. Quaresma are employees of Boehringer Ingelheim International GmbH, and M. Rieck is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG; they are responsible for the content of the letter and declare no other conflicts of interest. Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/EF18F06000BFF111.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stowasser, S., Quaresma, M. & Rieck, M. Comment on: ‘Pirfenidone Tablets in Idiopathic Pulmonary Fibrosis: A Profile of Their Use’. Drugs Ther Perspect 34, 192–193 (2018). https://doi.org/10.1007/s40267-018-0489-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0489-z

Search

Navigation